

Evotec launches transformation plan, targeting 75 million euros in savings by 2027 and revenue above 1 billion euros by 2030.
You can purchase shares of Evotec (NASDAQ:EVO) through any online brokerage.
Other companies in Evotec’s space includes: Thermo Fisher Scientific Inc (NYSE:TMO), Danaher Corp (NYSE:DHR), Agilent Technologies Inc (NYSE:A), Waters Corp (NYSE:WAT) and IQVIA Holdings Inc (NYSE:IQV).
Evotec has a consensus price target of $4.93.
The stock price for Evotec (NASDAQ: EVO) is $1.65 last updated November 5, 2026 at 5:31 AM EST.
There are no upcoming dividends for Evotec.
Evotec does not have any upcoming earnings scheduled.
There is no upcoming split for Evotec.
Evotec is in the Health Care sector and Life Sciences Tools & Services industry. They are listed on the NASDAQ.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other...